Analyst consensus rating
Aytu BioPharma Analyst Rating: none
AYTU is rated none by 3 analysts with a $9.50 target. As of 2026-09-01.
Direct answer
Aytu BioPharma's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $9.50.
Forecast evidence checked September 1, 2026.
Get free Aytu BioPharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.29
- Average price target
- $9.50
- High price target
- $14.50
- Low price target
- $7.00
- Low target gap
- +205.7%
- Target upside
- +314.8%
- High target gap
- +533.2%
- Target range width
- 327.5%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aytu BioPharma?
Aytu BioPharma has a verified none consensus. The same dataset has an average price target of $9.50.
How far are Aytu BioPharma's low and high targets from the recorded price?
The low target implies +205.7%, while the high target implies +533.2%.
How many analysts are included in Aytu BioPharma's consensus?
The verified consensus includes 3 analysts.
How is Aytu BioPharma's target upside or downside calculated?
The average target of $9.50 is divided by the recorded price of $2.29, then one is subtracted to produce +314.8%. This does not guarantee a future return.
When was Aytu BioPharma's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.